Divi's Laboratories Limited Logo

Divi's Laboratories Limited

DIVISLAB.NS

(2.2)
Stock Price

5.776,55 INR

0% ROA

12.74% ROE

88.07x PER

Market Cap.

1.472.569.816.450,00 INR

0% DER

0.54% Yield

20.43% NPM

Divi's Laboratories Limited Stock Analysis

Divi's Laboratories Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Divi's Laboratories Limited Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (23.73%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 PBV

With a remarkably low PBV ratio (0x), the stock offers substantial upside potential at a bargain price.

3 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Dividend

The company's consistent dividend payouts over the past five years exemplify its strong commitment to providing shareholders with reliable returns, making it an attractive investment option.

5 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (20.859), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

6 ROA

The stock's ROA (0%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

7 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

9 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

10 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

11 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

Divi's Laboratories Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Divi's Laboratories Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Divi's Laboratories Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Divi's Laboratories Limited Revenue
Year Revenue Growth
2005 3.811.107.000
2006 7.245.756.000 47.4%
2007 10.328.269.000 29.85%
2008 118.033.750.000 91.25%
2009 9.416.097.000 -1153.53%
2010 13.071.134.000 27.96%
2011 18.640.323.000 29.88%
2012 21.448.420.000 13.09%
2013 25.321.404.000 15.3%
2014 31.149.401.000 18.71%
2015 37.763.616.000 17.51%
2016 40.532.978.000 6.83%
2017 38.074.500.000 -6.46%
2018 48.038.200.000 20.74%
2019 52.911.700.000 9.21%
2020 68.583.400.000 22.85%
2021 87.992.300.000 22.06%
2022 71.120.000.000 -23.72%
2022 77.675.100.000 8.44%
2023 84.720.000.000 8.32%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Divi's Laboratories Limited Research and Development Expenses
Year Research and Development Expenses Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 159.809.000 100%
2011 188.592.000 15.26%
2012 239.987.000 21.42%
2013 253.913.000 5.48%
2014 276.616.000 8.21%
2015 309.235.000 10.55%
2016 431.175.000 28.28%
2017 101.100.000 -326.48%
2018 106.000.000 4.62%
2019 111.400.000 4.85%
2020 149.700.000 25.58%
2021 202.900.000 26.22%
2022 0 0%
2022 300.500.000 100%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Divi's Laboratories Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 1.078.913.000 100%
2011 1.066.210.000 -1.19%
2012 219.537.000 -385.66%
2013 295.153.000 25.62%
2014 342.025.000 13.7%
2015 378.798.000 9.71%
2016 428.040.000 11.5%
2017 905.300.000 52.72%
2018 542.300.000 -66.94%
2019 746.900.000 27.39%
2020 831.400.000 10.16%
2021 1.085.900.000 23.44%
2022 0 0%
2022 1.249.300.000 100%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Divi's Laboratories Limited EBITDA
Year EBITDA Growth
2005 1.205.023.000
2006 2.415.830.000 50.12%
2007 4.131.792.000 41.53%
2008 111.191.170.000 96.28%
2009 4.395.916.000 -2429.42%
2010 5.279.742.000 16.74%
2011 7.297.162.000 27.65%
2012 8.597.519.000 15.12%
2013 10.896.047.000 21.1%
2014 12.158.471.000 10.38%
2015 15.018.182.000 19.04%
2016 15.183.184.000 1.09%
2017 13.779.700.000 -10.19%
2018 20.001.200.000 31.11%
2019 19.556.700.000 -2.27%
2020 29.253.300.000 33.15%
2021 39.974.300.000 26.82%
2022 23.400.000.000 -70.83%
2022 27.124.800.000 13.73%
2023 24.920.000.000 -8.85%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Divi's Laboratories Limited Gross Profit
Year Gross Profit Growth
2005 1.781.220.000
2006 3.575.699.000 50.19%
2007 5.576.329.000 35.88%
2008 111.787.554.000 95.01%
2009 4.704.759.000 -2276.05%
2010 7.942.889.000 40.77%
2011 9.755.694.000 18.58%
2012 13.462.135.000 27.53%
2013 16.179.867.000 16.8%
2014 19.017.008.000 14.92%
2015 22.710.373.000 16.26%
2016 25.193.002.000 9.85%
2017 22.733.900.000 -10.82%
2018 29.786.000.000 23.68%
2019 31.826.300.000 6.41%
2020 45.342.600.000 29.81%
2021 58.320.900.000 22.25%
2022 43.600.000.000 -33.76%
2022 47.137.900.000 7.51%
2023 35.040.000.000 -34.53%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Divi's Laboratories Limited Net Profit
Year Net Profit Growth
2005 695.340.000
2006 1.858.570.000 62.59%
2007 3.475.984.000 46.53%
2008 4.166.418.000 16.57%
2009 3.403.365.000 -22.42%
2010 4.292.694.000 20.72%
2011 5.332.641.000 19.5%
2012 6.020.130.000 11.42%
2013 7.733.381.000 22.15%
2014 8.515.218.000 9.18%
2015 11.118.478.000 23.41%
2016 10.604.181.000 -4.85%
2017 8.770.100.000 -20.91%
2018 13.527.400.000 35.17%
2019 13.765.400.000 1.73%
2020 19.842.900.000 30.63%
2021 29.604.500.000 32.97%
2022 14.240.000.000 -107.9%
2022 18.240.000.000 21.93%
2023 17.200.000.000 -6.05%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Divi's Laboratories Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2005 3
2006 7 71.43%
2007 13 46.15%
2008 16 18.75%
2009 13 -23.08%
2010 16 18.75%
2011 20 20%
2012 23 9.09%
2013 29 24.14%
2014 32 9.38%
2015 42 23.81%
2016 40 -7.69%
2017 33 -18.18%
2018 51 34%
2019 52 1.96%
2020 75 31.08%
2021 112 33.33%
2022 54 -109.43%
2022 69 22.06%
2023 65 -6.25%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Divi's Laboratories Limited Free Cashflow
Year Free Cashflow Growth
2005 -620.287.000
2006 -3.324.024.000 81.34%
2007 1.213.973.000 373.81%
2008 1.907.848.000 36.37%
2009 3.091.749.000 38.29%
2010 1.638.344.000 -88.71%
2011 491.727.000 -233.18%
2012 1.246.021.000 60.54%
2013 3.102.983.000 59.84%
2014 5.191.195.000 40.23%
2015 6.421.934.000 19.16%
2016 7.726.133.000 16.88%
2017 5.019.800.000 -53.91%
2018 2.212.300.000 -126.9%
2019 327.300.000 -575.92%
2020 10.367.400.000 96.84%
2021 11.986.000.000 13.5%
2022 0 0%
2022 19.867.100.000 100%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Divi's Laboratories Limited Operating Cashflow
Year Operating Cashflow Growth
2005 488.029.000
2006 -1.820.715.000 126.8%
2007 2.924.740.000 162.25%
2008 3.011.459.000 2.88%
2009 3.693.495.000 18.47%
2010 3.265.521.000 -13.11%
2011 3.383.571.000 3.49%
2012 4.646.840.000 27.19%
2013 5.567.495.000 16.54%
2014 8.263.310.000 32.62%
2015 10.379.406.000 20.39%
2016 11.493.088.000 9.69%
2017 7.758.600.000 -48.13%
2018 9.543.000.000 18.7%
2019 12.159.400.000 21.52%
2020 19.469.300.000 37.55%
2021 19.118.000.000 -1.84%
2022 0 0%
2022 24.597.300.000 100%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Divi's Laboratories Limited Capital Expenditure
Year Capital Expenditure Growth
2005 1.108.316.000
2006 1.503.309.000 26.27%
2007 1.710.767.000 12.13%
2008 1.103.611.000 -55.02%
2009 601.746.000 -83.4%
2010 1.627.177.000 63.02%
2011 2.891.844.000 43.73%
2012 3.400.819.000 14.97%
2013 2.464.512.000 -37.99%
2014 3.072.115.000 19.78%
2015 3.957.472.000 22.37%
2016 3.766.955.000 -5.06%
2017 2.738.800.000 -37.54%
2018 7.330.700.000 62.64%
2019 11.832.100.000 38.04%
2020 9.101.900.000 -30%
2021 7.132.000.000 -27.62%
2022 0 0%
2022 4.730.200.000 100%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Divi's Laboratories Limited Equity
Year Equity Growth
2005 3.398.739.000
2006 5.354.126.000 36.52%
2007 8.613.970.000 37.84%
2008 12.413.844.000 30.61%
2009 15.178.038.000 18.21%
2010 17.974.775.000 15.56%
2011 21.315.223.000 15.67%
2012 25.005.966.000 14.76%
2013 29.633.497.000 15.62%
2014 34.953.598.000 15.22%
2015 42.876.958.000 18.48%
2016 53.573.943.000 19.97%
2017 59.248.000.000 9.58%
2018 69.571.500.000 14.84%
2019 73.099.200.000 4.83%
2020 92.946.100.000 21.35%
2021 117.281.800.000 20.75%
2022 127.670.900.000 8.14%
2022 0 0%
2023 135.710.000.000 100%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Divi's Laboratories Limited Assets
Year Assets Growth
2005 6.490.527.000
2006 8.435.521.000 23.06%
2007 11.787.213.000 28.43%
2008 15.482.502.000 23.87%
2009 18.588.541.000 16.71%
2010 22.747.760.000 18.28%
2011 27.566.574.000 17.48%
2012 31.387.646.000 12.17%
2013 37.104.917.000 15.41%
2014 44.051.454.000 15.77%
2015 49.684.357.000 11.34%
2016 61.585.337.000 19.32%
2017 67.831.500.000 9.21%
2018 80.382.500.000 15.61%
2019 85.357.000.000 5.83%
2020 107.740.700.000 20.78%
2021 133.747.100.000 19.44%
2022 144.387.700.000 7.37%
2022 0 0%
2023 0 0%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Divi's Laboratories Limited Liabilities
Year Liabilities Growth
2005 3.091.788.000
2006 3.081.395.000 -0.34%
2007 3.173.243.000 2.89%
2008 3.068.658.000 -3.41%
2009 3.410.503.000 10.02%
2010 4.772.985.000 28.55%
2011 6.251.351.000 23.65%
2012 6.381.680.000 2.04%
2013 7.471.420.000 14.59%
2014 9.097.856.000 17.88%
2015 6.807.399.000 -33.65%
2016 8.011.394.000 15.03%
2017 8.583.500.000 6.67%
2018 10.811.000.000 20.6%
2019 12.257.800.000 11.8%
2020 14.794.600.000 17.15%
2021 16.465.300.000 10.15%
2022 16.716.800.000 1.5%
2022 0 0%
2023 0 0%

Divi's Laboratories Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
308.32
Net Income per Share
62.98
Price to Earning Ratio
88.07x
Price To Sales Ratio
17.99x
POCF Ratio
387.52
PFCF Ratio
387.52
Price to Book Ratio
10.85
EV to Sales
18.44
EV Over EBITDA
60.31
EV to Operating CashFlow
397.25
EV to FreeCashFlow
397.25
Earnings Yield
0.01
FreeCashFlow Yield
0
Market Cap
1.472,57 Bil.
Enterprise Value
1.509,55 Bil.
Graham Number
851.14
Graham NetNet
139.3

Income Statement Metrics

Net Income per Share
62.98
Income Quality
0.23
ROE
0.13
Return On Assets
0
Return On Capital Employed
0
Net Income per EBT
0.73
EBT Per Ebit
1.07
Ebit per Revenue
0.26
Effective Tax Rate
0.26

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.01
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.5
Operating Profit Margin
0.26
Pretax Profit Margin
0.28
Net Profit Margin
0.2

Dividends

Dividend Yield
0.01
Dividend Yield %
0.54
Payout Ratio
0
Dividend Per Share
30

Operating Metrics

Operating Cashflow per Share
14.31
Free CashFlow per Share
14.31
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.12
Return on Tangible Assets
0
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
139,30
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
511.21
Interest Debt per Share
0.11
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
1.48
Current Ratio
0
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
36,98 Bil.
Invested Capital
36980000000
Working Capital
36,98 Bil.
Intangibles to Total Assets
0
Average Receivables
10,78 Bil.
Average Payables
4,12 Bil.
Average Inventory
15920000000
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Divi's Laboratories Limited Dividends
Year Dividends Growth
2003 6
2004 8 25%
2005 8 0%
2006 10 20%
2007 10 0%
2008 4 -150%
2009 6 33.33%
2010 6 0%
2011 10 40%
2012 13 23.08%
2013 15 13.33%
2014 20 25%
2015 20 0%
2016 10 -100%
2017 10 0%
2018 10 0%
2019 16 37.5%
2020 16 0%
2021 20 20%
2022 30 33.33%
2023 30 0%
2024 30 0%

Divi's Laboratories Limited Profile

About Divi's Laboratories Limited

Divi's Laboratories Limited manufactures and sells generic active pharmaceutical ingredients (APIs) and intermediates, and nutraceutical ingredients in India, the United States, Asia, Europe, and internationally. It also undertakes custom synthesis of APIs and intermediates; and supplies a range of carotenoids, as well as markets vitamins to nutritional, pharma, food/beverage, and feed industries. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. The company was incorporated in 1990 and is headquartered in Hyderabad, India.

CEO
Dr. Kiran Satchandra Divi B. P
Employee
9.741
Address
Divi Towers
Hyderabad, 500032

Divi's Laboratories Limited Executives & BODs

Divi's Laboratories Limited Executives & BODs
# Name Age
1 Mr. L. Ramesh Babu LLB, M.Com, MBA
Vice President of Procurement & Chief Information Officer
70
2 Dr. Kiran Satchandra Divi B. Pharm., M.Pharm
Chief Executive Officer & Whole-Time Director
70
3 Mr. Venkata Ramana Nimmagadda B.Sc.(Chem)
Executive Director
70
4 Ms. Nilima Prasad Divi
Whole-time Director, Chief Control Officer & Director of Commercial
70
5 Dr. Devendra Rao Sureddy M.Sc.
Whole-Time Director (Manufacturing)
70
6 Mr. Satya Prakash Divi B.Tech (Mech), MBA, MS (CIS)
Vice President of Sales, Marketing & Logistics
70
7 Mr. M. Satish Choudhury
Company Secretary & Compliance Officer
70
8 Mr. L. Kishore Babu B.Com, FCMA, FICWA
Chief Financial Officer
70
9 Dr. Murali Krishna Prasad Divi M. Pharm, Ph.D.
MD & Executive Director
70
10 Mr. Y. T. S. Prasad B.E.
Global Quality Head
70

Divi's Laboratories Limited Competitors

Pidilite Industries Limited Logo
Pidilite Industries Limited

PIDILITIND.NS

(4.0)
Asian Paints Limited Logo
Asian Paints Limited

ASIANPAINT.NS

(3.8)
Cipla Limited Logo
Cipla Limited

CIPLA.NS

(3.0)
Titan Company Limited Logo
Titan Company Limited

TITAN.NS

(2.8)